Acrivon has an AP3-guided oncology platform, a lead ACR-368 endometrial-cancer catalyst, and cash runway into Q3 2027, but it is still pre-revenue and dependent on clinical data, diagnostics, and future financing.
The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.
